Pharsight

Kuvan generic

Kuvan is an anti-hyperphenylalaninemia drug owned by Biomarin Pharm. The active ingredient of the drug is sapropterin dihydrochloride. The drug was first authorized for market use on 19 December, 2013. Kuvan is available in powder; oral dosage forms.

When will Kuvan generic be available?

The generic version of Kuvan might become available after 01 May, 2033. This is based on the expiration date of the last active patent, US9216178*PED, which is due to expire on 01 May, 2033. It's worth noting that the generic release could be earlier if there's a Para IV filing.

Kuvan uses

Kuvan is used for reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia. It is effective in patients with hyperphenylalaninemia due to tetrahydrobiopterin-responsive phenylketonuria. To achieve optimal results, Kuvan should be taken orally with food to increase absorption.

Kuvan patent expiration

Kuvan has a total of 20 drug patents. None of these patents have expired, and the latest patent will expire on 01 May, 2033. To get better insight, it is suggested to look at each patent in detail. Below are the details of each patent:

EPO Oppostions filed on Kuvan

Kuvan dosage

Want to ask something?